Specifically, decreased IDO levels in melanoma patients are associated with shorter overall survival, increased recurrence rates, and accelerated tumor progression, further emphasizing the critical role of inflammation in driving melanoma pathogenesis [19,20]. The gene discussed is IDO1; the disease is neoplasm.